SARS-CoV-2 specific antibodies persist for five months in mild cases
In a study of mild-to-moderate COVID-19 patients scientists established that the level of certain antibodies remained stable for five months.
List view / Grid view
In a study of mild-to-moderate COVID-19 patients scientists established that the level of certain antibodies remained stable for five months.
According to the study, the transcription factor IRF4 drives T cell differentiation and immunosuppression in multiple human cancers.
Researchers used flow cytometry to characterise which types of T cells are involved in the immune response to COVID-19 and what they target.
Our full gene-to-protein workflow can support your research for rapid protein production early during drug development so you can minimize changes from R&D to bioproduction.
Enosi Life Science researchers Sir Marc Feldmann, Dr H Michael Shepard and Dr Fiona McCann explain why anti-TNF therapies may be effective in treating COVID-19 associated cytokine storms and other inflammatory conditions.
An analysis reveals that in comparison to other inflammatory diseases such as cytokine-release syndrome (CRS) and sepsis, the levels of cytokines in severely ill COVID-19 patients is low.
Researchers reveal that SARS-CoV-2 is more infectious than SARS-CoV because it can use both ACE2 and neuropilin-1 to infect cells.
Scientists who developed the E22W42 DC vaccine suggest it could be safer and more effective than previous anti-amyloid Alzheimer’s therapies.
Topical delivery of a small interfering RNA (siRNA) using an ionic liquid complex significantly reduced levels of inflammatory cytokines and symptoms of psoriasis.
The team demonstrated that expression of Bach2 protein and reduced mTORC1 activity is necessary for germinal B cells to become memory B cells.
Water immersion objectives are essential for capturing more data at greater depths in 3D structures, such as spheroids and thick tissues.
A common SARS-CoV-2 mutation known as D614G should not impact on the efficacy of COVID-19 vaccines, a study has shown.
Two separate studies show that IgG serotype antibodies targeting the SARS-CoV-2 spike protein are still detectable in patient’s blood and saliva after 90 days.
Researchers studied 180 convalescent COVID-19 patients to reveal T-cell epitopes that they say can be targeted by a vaccine.
Researchers used CRISPR gene-editing to develop a vaccine able to protect against the spread of the Leishmania major parasite which causes cutaneous leishmaniasis.